Supportive Care in Cancer

, Volume 21, Issue 11, pp 3137–3142 | Cite as

Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation

  • Tove Godskesen
  • Peter Nygren
  • Karin Nordin
  • Mats Hansson
  • Ulrik Kihlbom
Original Article

Abstract

Background

In cancer, phase 1 clinical trials on new drugs mostly involve patients with advanced disease that is unresponsive to standard therapy. The purpose of this study was to explore the difficult ethical problems related to patient information and motives for participation in such trials.

Method

A descriptive and explorative qualitative design was used. Fourteen cancer patients from three different phase 1 trials in end-stage cancer were interviewed. The interviews were analysed using qualitative content analysis.

Results

The patients expressed unrealistic expectations of therapeutic benefit and inadequate understanding of the trials’ purpose, so-called therapeutic misconception. However, they reported a positive attitude towards participation. Thus, the patients valued the close and unique medical and psychological attention they received by participating. Participation also made them feel unique and notable.

Conclusions

Patients with end-stage cancer participating in phase 1 clinical trials are unaware of the very small potential for treatment benefit and the risk of harm. Trial participation may offer hope and social–emotional support and a strategy for coping with the emotional stress associated with advanced cancer and may, consequently, improve emotional well-being.

Keywords

Cancer Clinical trials Ethics Sweden 

References

  1. 1.
    Appelbaum PS, Roth LH, Lidz C (1982) The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 5:319–329PubMedCrossRefGoogle Scholar
  2. 2.
    Beauchamp TL, Childress JF (2009) Principles of biomedical ethics. Oxford University Press, New YorkGoogle Scholar
  3. 3.
    Cohen L, de Moor C, Amato RJ (2001) The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a phase I cancer clinical trial. Cancer 91:1949–1955PubMedCrossRefGoogle Scholar
  4. 4.
    Cox K (2000) Enhancing cancer clinical trial management: recommendations from a qualitative study of trial participants’ experiences. Psychooncol 9:314–322CrossRefGoogle Scholar
  5. 5.
    Cox K (2002) Informed consent and decision-making: patients’ experiences of the process of recruitment to phases I and II anti-cancer drug trials. Patient Educ Couns 46:31–38PubMedCrossRefGoogle Scholar
  6. 6.
    Daugherty CK (1999) Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J Clin Oncol 17:1601–1617PubMedGoogle Scholar
  7. 7.
    Daugherty CK, Banik DM, Janish L, Ratain MJ (2000) Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB 22:6–14PubMedCrossRefGoogle Scholar
  8. 8.
    Eriksson K (2001) Vårdvetenskap som akademisk disciplin. (Health care science as an academic discipline). Åbo Akademi University, TurkuGoogle Scholar
  9. 9.
    Fussenich LM, Desar IM, Peters ME, Teerenstra S, van der Graaf WT, Timmer-Bonte JN, van Herpen CM (2011) A new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer 47:1152–1160PubMedCrossRefGoogle Scholar
  10. 10.
    Grady C (2005) Payment of clinical research subjects. J Clin Invest 115:1681–1687PubMedCrossRefGoogle Scholar
  11. 11.
    Graneheim UH, Lundman B (2004) Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today 24:105–112PubMedCrossRefGoogle Scholar
  12. 12.
    Han C, Braybrooke JP, Deplanque G, Taylor M, Mackintosh D, Kaur K, Samouri K, Ganesan TS, Harris AL, Talbot DC (2003) Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Brit J Cancer 89:1166–1171PubMedCrossRefGoogle Scholar
  13. 13.
    Horng S, Emanuel EJ, Wilfond B, Rackoff J, Martz K, Grady C (2002) Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med 347:2134–2140PubMedCrossRefGoogle Scholar
  14. 14.
    Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, Magne N, Pignon JP, Vassal G, Armand JP, Soria JC (2008) Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19:787–792PubMedCrossRefGoogle Scholar
  15. 15.
    Jenkins V, Solis-Trapala I, Langridge C, Catt S, Talbot DC, Fallowfield LJ (2011) What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions. J Clin Oncol 29:61–68PubMedCrossRefGoogle Scholar
  16. 16.
    Kahneman D, Tversky A (1979) Prospect theory—analysis of decision under risk. Econometrica 47:263–291CrossRefGoogle Scholar
  17. 17.
    Kass N, Taylor H, Fogarty L, Sugarman J, Goodman SN, Goodwin-Landher A, Carducci M, Hurwitz H (2008) Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics 3:57–68PubMedCrossRefGoogle Scholar
  18. 18.
    Kvale S (1997) Den kvalitativa forskningsintervjun. Studentlitteratur, LundGoogle Scholar
  19. 19.
    Kvale S (2007) Doing interviews. Sage, Thousand OaksGoogle Scholar
  20. 20.
    Le Tourneau C, Dieras V, Tresca P, Cacheux W, Paoletti X (2010) Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Target Oncol 5:65–72PubMedCrossRefGoogle Scholar
  21. 21.
    Mcgraw JG (1995) Loneliness, its nature and forms—an existential perspective. Man World 28:43–64CrossRefGoogle Scholar
  22. 22.
    Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB, Castel L, Corbett S, Diefenbach M, Gaskin D, Li Y, Manne S, Marshall J, Rowland JH, Slater E, Sulmasy DP, Van Echo D, Washington S, Schulman KA (2003) Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician–patient communication. J Clin Oncol 21:2589–2596PubMedCrossRefGoogle Scholar
  23. 23.
    Moore S (2001) A need to try everything: patient participation in phase I trials. J Adv Nurs 33:738–747PubMedCrossRefGoogle Scholar
  24. 24.
    Ohlen J (2002) Practical wisdom: competencies required in alleviating suffering in palliative care. J Palliat Care 18:293–299PubMedGoogle Scholar
  25. 25.
    Patton MQ (2002) Qualitative research and evaluation methods. Sage, LondonGoogle Scholar
  26. 26.
    Saeteren B, Lindstrom UA, Naden D (2011) Latching onto life: living in the area of tension between the possibility of life and the necessity of death. J Clin Nurs 20:811–818PubMedCrossRefGoogle Scholar
  27. 27.
    Stolberg SG (2000) Teenager’s death is shaking up field of human gene-therapy experiments. New York Times, New YorkGoogle Scholar
  28. 28.
    Sulmasy DP, Astrow AB, He MK, Seils DM, Meropol NJ, Micco E, Weinfurt KP (2010) The culture of faith and hope patients’ justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer 116:3702–3711PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Tove Godskesen
    • 1
  • Peter Nygren
    • 2
  • Karin Nordin
    • 3
    • 4
  • Mats Hansson
    • 1
  • Ulrik Kihlbom
    • 1
  1. 1.Centre for Research Ethics & BioethicsUppsala UniversityUppsalaSweden
  2. 2.Department of Radiology, Oncology, and Radiation SciencesUppsala UniversityUppsalaSweden
  3. 3.Department of Public Health and Caring SciencesUppsala UniversityUppsalaSweden
  4. 4.Department of Global Public Health and Primary CareUniversity of BergenBergenNorway

Personalised recommendations